NeuroPace Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Public

  • Employees
  • 216

Employees

  • Stock Symbol
  • NPCE

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $7.95
  • (As of Friday Closing)

NeuroPace General Information

Description

NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 455 North Bernardo Avenue
  • Mountain View, CA 94043
  • United States
+1 (650)
Primary Industry
Diagnostic Equipment
Other Industries
Monitoring Equipment
Other Healthcare Technology Systems
Stock Exchange
NAS
Corporate Office
  • 455 North Bernardo Avenue
  • Mountain View, CA 94043
  • United States
+1 (650)

NeuroPace Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NeuroPace Stock Performance

As of 20-Nov-2026, NeuroPace’s stock price is $7.95. Its current market cap is $274M with 34.5M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$7.95 $8.14 $5.46 - $19.60 $274M 34.5M 269K -$0.56

NeuroPace Financials Summary

As of 30-Sep-2026, NeuroPace has a trailing 12-month revenue of $107M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 490,534 525,438 350,669 281,331
Revenue 106,746 99,986 79,906 65,421
EBITDA (8,442) (14,876) (19,598) (25,884)
Net Income (18,916) (21,465) (27,141) (32,956)
Total Assets 94,775 105,565 94,647 107,651
Total Debt 69,540 70,837 73,338 72,395
Public Fundamental Data provided by Morningstar, Inc. disclaimer

NeuroPace Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore NeuroPace‘s full profile, request access.

Request a free trial

NeuroPace Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore NeuroPace‘s full profile, request access.

Request a free trial

NeuroPace Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing o
Diagnostic Equipment
Mountain View, CA
216 As of 2026

Rockville, MD
 

Enschede, Netherlands
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

NeuroPace Competitors (9)

One of NeuroPace’s 9 competitors is BrainScope, a Venture Capital-Backed company based in Rockville, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BrainScope Venture Capital-Backed Rockville, MD
Finapres Medical Systems Corporate Backed or Acquired Enschede, Netherlands
DexCom Formerly VC-backed San Diego, CA
Emteq Labs Venture Capital-Backed Brighton, United Kingdom
Neuspera Venture Capital-Backed San Jose, CA
You’re viewing 5 of 9 competitors. Get the full list »

NeuroPace Patents

NeuroPace Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260077198-A1 Systems, devices, and methods for determining treatment for a neurological disorder Pending 16-Sep-2024
US-20260273288-A1 System and methods for determining and tuning detection settings in a neurostimulator Pending 22-May-2024
US-20250359812-A1 System and methods for proposing detection parameters for detecting epileptiform activity Pending 22-May-2024
US-20250229090-A1 Implantable medical device with a slot antenna Pending 12-Jan-2024
WO-2025151324-A1 Implantable medical device with a slot antenna Inactive 12-Jan-2024 A61N1/37217
To view NeuroPace’s complete patent history, request access »

NeuroPace Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NeuroPace Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore NeuroPace‘s full profile, request access.

Request a free trial

NeuroPace Investments (1)

NeuroPace’s most recent deal was a Later Stage VC with Epicor Medical for . The deal was made on 12-May-2003.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Epicor Medical 12-May-2003 Later Stage VC Other Devices and Supplies
To view NeuroPace’s complete investments history, request access »

NeuroPace ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

39.41 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Healthcare

Industry

of 590

Rank

Percentile

Medical Devices

Subindustry

of 209

Rank

Percentile

To view NeuroPace’s complete esg history, request access »

NeuroPace Exits (1)

NeuroPace’s most recent exit was on 12-May-2003 from Epicor Medical. The exit was categorized as with 9 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Epicor Medical 12-May-2003 Completed
  • 9 buyers
To view NeuroPace’s complete exits history, request access »

NeuroPace FAQs

  • When was NeuroPace founded?

    NeuroPace was founded in 1997.

  • Where is NeuroPace headquartered?

    NeuroPace is headquartered in Mountain View, CA.

  • What is the size of NeuroPace?

    NeuroPace has 216 total employees.

  • What industry is NeuroPace in?

    NeuroPace’s primary industry is Diagnostic Equipment.

  • Is NeuroPace a private or public company?

    NeuroPace is a Public company.

  • What is NeuroPace’s stock symbol?

    The ticker symbol for NeuroPace is NPCE.

  • What is the current stock price of NeuroPace?

    As of 20-Nov-2026 the stock price of NeuroPace is $7.95.

  • What is the current market cap of NeuroPace?

    The current market capitalization of NeuroPace is $274M.

  • What is NeuroPace’s current revenue?

    The trailing twelve month revenue for NeuroPace is $107M.

  • Who are NeuroPace’s competitors?

    BrainScope, Finapres Medical Systems, DexCom, Emteq Labs, and Neuspera are some of the 9 competitors of NeuroPace.

  • What is NeuroPace’s annual earnings per share (EPS)?

    NeuroPace’s EPS for 12 months was -$0.56.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process